EMA Application withdrawn: Infinia (alpha-1-antitrypsin) — Kamada BioPharma Limited at Fieldfisher LLP

View source ↗

Summary

The EMA application for Infinia (alpha-1-antitrypsin) by Kamada BioPharma Limited at Fieldfisher LLP was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Diseases
• Lung Diseases

Drugs mentioned

• Infinia (alpha-1-antitrypsin)

Snippet

Status: Application withdrawn. Therapeutic area: Genetic Diseases, Inborn;Lung Diseases. MAH: Kamada BioPharma Limited at Fieldfisher LLP. Decision date: 23/06/2017. Orphan medicine